old couple relaxing on the beach parkinson's case study


Share This Post

Alzheimer’s disease is linked to the build-up of an abnormal protein in the brain called amyloid beta. Early on, this process doesn’t cause any obvious symptoms. But later, cognitive problems such as memory loss may emerge. The question is, could targeting amyloid beta prevent this?

To answer this question and more, we need your help. We’re looking for people to join a clinical research study called SKYLINE. The SKYLINE Study will evaluate this investigational drug that targets amyloid beta. To take part, you must be between the ages of 60-80 years old and not be experiencing any memory or thought-processing problems. You cannot be diagnosed with Mild Cognitive Impairment (MCI), Alzheimer’s, or dementia.

If you’re interested in taking part, we’d like to first conduct some screening assessments to make sure that you and the study are a good fit (together). For example, we’d measure the amount of amyloid beta in your brain, as only people with a certain level can join this study. If you are eligible, then you’ll be officially invited to join the study. Once you join, you’ll receive subcutaneous (under the skin) injections containing the study medication (either the investigational drug or a placebo). A placebo looks just like the investigational drug, but contains no active ingredients.

old couple wearing swimming gear parkinson's disease study

Are You Willing To Learn More About Your Risk?

For the first 9 months of SKYLINE, the amount of study medication will gradually increase until it reaches the target dose. After 9 months, you’ll then follow your chosen study treatment schedule of one injection of study medication every week, or two injections, at the same time, every two weeks, for the remaining 43 months. This may sound like a long time, but it can be many years before someone with rising levels of amyloid beta begins to display any outward signs.

Please be aware that participants who experience Alzheimer’s symptoms (and have reached the target dose of the study medication) will be given the investigational drug, even if they were given it before.

If this study sounds interesting to you or someone you know, please contact us today for a confidential and no-obligation chat. We’re particularly interested in hearing from people with a family history of dementia, and participation is entirely voluntary. It’s also worth noting that all study medication and assessments would be provided to you at no cost, and health insurance is not required.

We’re Proud To Be Local With SNN, The Suncoast News Network. They’re Here To Help Support Your Community! Follow Us On Facebook To Learn More.
BRC Newsletter Icon bradenton research center 1


Sign up below to stay connected.

Your Questions Answered

Wellness Wednesday

Do you have a health question or wellness topic that you would like to discuss?

Why Health Matters

Get the latest news from the Bradenton Research Center.
Click Here

More To Explore


3924 9th Ave W, Bradenton, FL 34205

Call Us

(941) 708-0005

Email Us